The Importance of Continuing Breastfeeding during Coronavirus Disease-2019: In Support of the World Health Organization Statement on Breastfeeding during the Pandemic

AGA Rapid Recommendations for Gastrointestinal Procedures During the COVID-19 Pandemic

Electrocardiographic features of patients with COVID-19: One year of unexpected manifestations

Clinical outcomes and serologic response in solid organ transplant recipients with COVID-19: A case series from the United States.

Severe Acute Respiratory Syndrome Coronavirus-2 Cardiovascular Complications: Implications for Cardiothoracic Anesthesiology

Controversies in airway management of COVID-19 patients: updated information and international expert consensus recommendations

COVID-19 vasculitis and novel vasculitis mimics.

Evidence of potent humoral immune activity in COVID-19-infected kidney transplant recipients.

Testing the Asymptomatic Pre-Surgical Population for Severe Acute Respiratory Syndrome Coronavirus 2

Plasma exchange and COVID 19

The coronavirus disease 2019 (COVID-19) pandemic constitutes a global health emergency. Currently, there are no completely effective therapeutic medications for the management of this outbreak. The cytokine storm is a hyperinflammatory medical condition due to excessive and uncontrolled release of pro-inflammatory cytokines in patients suffering from severe COVID-19, leading to the development of acute respiratory distress syndrome (ARDS) and multiple organ dysfunction syndrome (MODS) and even mortality. Understanding the pathophysiology of COVID-19 can be helpful for the treatment of patients. Evidence suggests that the levels of tumor necrosis factor alpha (TNF-α) and interleukin (IL)-1 and IL-6 are dramatically different between mild and severe patients, so they may be important contributors to the cytokine storm. Several serum markers can be predictors for the cytokine storm. This review discusses the cytokines involved in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, focusing on interferons (IFNs) and ILs, and whether they can be used in COVID-19 treatment. Moreover, we highlight several microRNAs that are involved in these cytokines and their role in the cytokine storm caused by COVID-19.

Use of ECMO in Patients With Coronavirus Disease 2019: Does the Evidence Suffice?

The Right Ventricle in COVID-19 Lung Injury: Proposed Mechanisms, Management, and Research Gaps

Targeting the Gut Microbiota in Coronavirus Disease 2019: Hype or Hope?

COVID-19: What do we know?

Immune mechanisms of pulmonary intravascular coagulopathy in COVID-19 pneumonia.